Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (41)
  • Allergen immunotherapy (81)
  • AllergoOncology (15)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (235)
  • Allied health and primary care (20)
  • Anaphylaxis (113)
  • Artificial Intelligence (12)
  • Asthma (185)
  • Basic immunology (58)
  • Biologicals (90)
  • Biomarkers (64)
  • Comparative veterinary allergology (1)
  • COVID19 (11)
  • Dermatology (125)
  • Drug allergy (172)
  • ENT (29)
  • Environmental allergy and climate change (31)
  • Eosinophilic esophagitis (21)
  • Epidemiology (66)
  • Epithelial cell biology (8)
  • Food allergy (195)
  • Genomics and proteomics (17)
  • x Immune deficiencies and autoimmunity (80)
  • Immunomodulation and nutrition (13)
  • Infections (27)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (24)
  • Microbiome (9)
  • Occupational allergy (27)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (144)
  • Prevention (40)
  • x Systems medicine (13)
Poster available until
  • Until platform closure (9)
Poster categories
  • e-Thematic Poster Session (7)
  • Thematic Poster Session (82)
keywords
Session Reference
  • L-TPS05 (1)
  • L-TPS06 (8)
  • L-TPS07 (2)
  • L-TPS08 (1)
  • L-TPS11 (3)
  • L-TPS17 (1)
  • L-TPS18 (1)
  • L-TPS20 (3)
  • L-TPS21 (5)
  • TPS11 (1)
  • TPS15 (3)
  • TPS16 (14)
  • TPS17 (2)
  • TPS28 (2)
  • TPS31 (1)
  • TPS39 (1)
  • TPS40 (12)
  • TPS41 (5)
  • TPS49 (1)
  • TPS52 (1)
  • TPS54 (2)
  • TPS56 (2)
  • TPS57 (1)
  • TPS65 (8)
  • TPS67 (1)
  • TPS68 (2)
  • TPS69 (1)
92 results
Thumbnail

D2.324 - Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study

Thumbnail

D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Thumbnail

D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Thumbnail

D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam

Thumbnail

D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes

Thumbnail

D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials

Thumbnail

D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Thumbnail

D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Thumbnail

D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia

Thumbnail

D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)

Thumbnail

D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients

Thumbnail

D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health

Thumbnail

D2.340 - A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden

Thumbnail

D1.332 - Hereditary Angioedema in Ukraine

Thumbnail

D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach

Thumbnail

D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia

Thumbnail

D1.335 - TeloNet is born; why immunologists should know about telomere disorders

Thumbnail

D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)

Thumbnail

D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM